In a phase III trial of olaparib (POLO trial), metastatic PC patients with germline BRCA1/BRCA2 mutation who do not experience disease progression after a platinum-based regimen for 16 weeks or more are randomized to olaparib 300 mg twice daily or placebo (NCT02184195). This evidence concerns the gene BRCA2 and pachyonychia congenita.